Dopamine receptor antagonism by the novel anti-anxiety drug, buspirone

B. A. McMillen, R. T. Matthews, M. K. Sanghera, P. D. Shepard, D. C. German

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Buspirone is an anxiolytic drug with a clinical potency similar to that of diazepam, but it lacks affinity for diazepam of γ-aminobutyric acid (GABA) binding sites. Because previous reports suggested that buspirone may possess dopamine (DA) agonist activity, buspirone was tested for effects of DA neurotransmission. At presynaptic DA receptors, unlike other DA agnostis, buspirone inhibited neither synaptosomal tyrosine hydroxylase activity nor the in vivo γ-butyrolactone-induced activation of striatal tyrosine hydroxylase. However, buspirone did inhibit the action of apomorphine, a direct acting DA agonist in both of these DA autoreceptor test systems with a potency similar to that of chlorpromazine. Striatal DA synthesis and metabolism were markedly increased by buspirone treatment; the maximum effective dose was 3.0 mg/kg, s.c., which caused a 400% increase. Extracellular single cell recordings showed that buspirone, administered intravenously, markedly increased substantia nigra DA neuronal impulse flow and potently reversed inhibition of DA cell impulse flow caused by systemic injection of apomorphine (5 to 10 μg/kg). Inhibition of DA cell impulse flow by iontophoresis of DA was reversed by iontophoretic administration of buspirone, but buspirone did not interfere with the ability of GABA to inhibit DA impulse flow. That buspirone interacts with receptor sites in addition to the DA autoreceptor was indicated by the finding that after DA receptor blockade with haloperidol, buspirone further enhanced DA neuronal impulse flow. Buspirone did not cause catalepsy and did not inhibit apomorphine-induced turning in rats with unilateral 6-hydroxydopamine lesions of the substantia nigra, which indicated that the drug has minimal action at the classical postsynaptic DA receptor. These data suggest that (a) buspirone enhances DA neuronal activity, in part, by weakly inhibiting presynaptic DA receptors, and (b) buspirone has minimal effects on postsynaptic DA receptors.

Original languageEnglish (US)
Pages (from-to)733-738
Number of pages6
JournalJournal of Neuroscience
Volume3
Issue number4
StatePublished - 1983

Fingerprint

Buspirone
Anti-Anxiety Agents
Dopamine Receptors
Dopamine
Apomorphine
Presynaptic Receptors
Corpus Striatum
Autoreceptors
Dopamine Agonists
Tyrosine 3-Monooxygenase
Substantia Nigra
Diazepam
gamma-Aminobutyric Acid
Aminobutyrates
Catalepsy
Iontophoresis
Oxidopamine
Chlorpromazine
Haloperidol
Synaptic Transmission

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

McMillen, B. A., Matthews, R. T., Sanghera, M. K., Shepard, P. D., & German, D. C. (1983). Dopamine receptor antagonism by the novel anti-anxiety drug, buspirone. Journal of Neuroscience, 3(4), 733-738.

Dopamine receptor antagonism by the novel anti-anxiety drug, buspirone. / McMillen, B. A.; Matthews, R. T.; Sanghera, M. K.; Shepard, P. D.; German, D. C.

In: Journal of Neuroscience, Vol. 3, No. 4, 1983, p. 733-738.

Research output: Contribution to journalArticle

McMillen, BA, Matthews, RT, Sanghera, MK, Shepard, PD & German, DC 1983, 'Dopamine receptor antagonism by the novel anti-anxiety drug, buspirone', Journal of Neuroscience, vol. 3, no. 4, pp. 733-738.
McMillen BA, Matthews RT, Sanghera MK, Shepard PD, German DC. Dopamine receptor antagonism by the novel anti-anxiety drug, buspirone. Journal of Neuroscience. 1983;3(4):733-738.
McMillen, B. A. ; Matthews, R. T. ; Sanghera, M. K. ; Shepard, P. D. ; German, D. C. / Dopamine receptor antagonism by the novel anti-anxiety drug, buspirone. In: Journal of Neuroscience. 1983 ; Vol. 3, No. 4. pp. 733-738.
@article{368e445769d144a0addf020541125278,
title = "Dopamine receptor antagonism by the novel anti-anxiety drug, buspirone",
abstract = "Buspirone is an anxiolytic drug with a clinical potency similar to that of diazepam, but it lacks affinity for diazepam of γ-aminobutyric acid (GABA) binding sites. Because previous reports suggested that buspirone may possess dopamine (DA) agonist activity, buspirone was tested for effects of DA neurotransmission. At presynaptic DA receptors, unlike other DA agnostis, buspirone inhibited neither synaptosomal tyrosine hydroxylase activity nor the in vivo γ-butyrolactone-induced activation of striatal tyrosine hydroxylase. However, buspirone did inhibit the action of apomorphine, a direct acting DA agonist in both of these DA autoreceptor test systems with a potency similar to that of chlorpromazine. Striatal DA synthesis and metabolism were markedly increased by buspirone treatment; the maximum effective dose was 3.0 mg/kg, s.c., which caused a 400{\%} increase. Extracellular single cell recordings showed that buspirone, administered intravenously, markedly increased substantia nigra DA neuronal impulse flow and potently reversed inhibition of DA cell impulse flow caused by systemic injection of apomorphine (5 to 10 μg/kg). Inhibition of DA cell impulse flow by iontophoresis of DA was reversed by iontophoretic administration of buspirone, but buspirone did not interfere with the ability of GABA to inhibit DA impulse flow. That buspirone interacts with receptor sites in addition to the DA autoreceptor was indicated by the finding that after DA receptor blockade with haloperidol, buspirone further enhanced DA neuronal impulse flow. Buspirone did not cause catalepsy and did not inhibit apomorphine-induced turning in rats with unilateral 6-hydroxydopamine lesions of the substantia nigra, which indicated that the drug has minimal action at the classical postsynaptic DA receptor. These data suggest that (a) buspirone enhances DA neuronal activity, in part, by weakly inhibiting presynaptic DA receptors, and (b) buspirone has minimal effects on postsynaptic DA receptors.",
author = "McMillen, {B. A.} and Matthews, {R. T.} and Sanghera, {M. K.} and Shepard, {P. D.} and German, {D. C.}",
year = "1983",
language = "English (US)",
volume = "3",
pages = "733--738",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "4",

}

TY - JOUR

T1 - Dopamine receptor antagonism by the novel anti-anxiety drug, buspirone

AU - McMillen, B. A.

AU - Matthews, R. T.

AU - Sanghera, M. K.

AU - Shepard, P. D.

AU - German, D. C.

PY - 1983

Y1 - 1983

N2 - Buspirone is an anxiolytic drug with a clinical potency similar to that of diazepam, but it lacks affinity for diazepam of γ-aminobutyric acid (GABA) binding sites. Because previous reports suggested that buspirone may possess dopamine (DA) agonist activity, buspirone was tested for effects of DA neurotransmission. At presynaptic DA receptors, unlike other DA agnostis, buspirone inhibited neither synaptosomal tyrosine hydroxylase activity nor the in vivo γ-butyrolactone-induced activation of striatal tyrosine hydroxylase. However, buspirone did inhibit the action of apomorphine, a direct acting DA agonist in both of these DA autoreceptor test systems with a potency similar to that of chlorpromazine. Striatal DA synthesis and metabolism were markedly increased by buspirone treatment; the maximum effective dose was 3.0 mg/kg, s.c., which caused a 400% increase. Extracellular single cell recordings showed that buspirone, administered intravenously, markedly increased substantia nigra DA neuronal impulse flow and potently reversed inhibition of DA cell impulse flow caused by systemic injection of apomorphine (5 to 10 μg/kg). Inhibition of DA cell impulse flow by iontophoresis of DA was reversed by iontophoretic administration of buspirone, but buspirone did not interfere with the ability of GABA to inhibit DA impulse flow. That buspirone interacts with receptor sites in addition to the DA autoreceptor was indicated by the finding that after DA receptor blockade with haloperidol, buspirone further enhanced DA neuronal impulse flow. Buspirone did not cause catalepsy and did not inhibit apomorphine-induced turning in rats with unilateral 6-hydroxydopamine lesions of the substantia nigra, which indicated that the drug has minimal action at the classical postsynaptic DA receptor. These data suggest that (a) buspirone enhances DA neuronal activity, in part, by weakly inhibiting presynaptic DA receptors, and (b) buspirone has minimal effects on postsynaptic DA receptors.

AB - Buspirone is an anxiolytic drug with a clinical potency similar to that of diazepam, but it lacks affinity for diazepam of γ-aminobutyric acid (GABA) binding sites. Because previous reports suggested that buspirone may possess dopamine (DA) agonist activity, buspirone was tested for effects of DA neurotransmission. At presynaptic DA receptors, unlike other DA agnostis, buspirone inhibited neither synaptosomal tyrosine hydroxylase activity nor the in vivo γ-butyrolactone-induced activation of striatal tyrosine hydroxylase. However, buspirone did inhibit the action of apomorphine, a direct acting DA agonist in both of these DA autoreceptor test systems with a potency similar to that of chlorpromazine. Striatal DA synthesis and metabolism were markedly increased by buspirone treatment; the maximum effective dose was 3.0 mg/kg, s.c., which caused a 400% increase. Extracellular single cell recordings showed that buspirone, administered intravenously, markedly increased substantia nigra DA neuronal impulse flow and potently reversed inhibition of DA cell impulse flow caused by systemic injection of apomorphine (5 to 10 μg/kg). Inhibition of DA cell impulse flow by iontophoresis of DA was reversed by iontophoretic administration of buspirone, but buspirone did not interfere with the ability of GABA to inhibit DA impulse flow. That buspirone interacts with receptor sites in addition to the DA autoreceptor was indicated by the finding that after DA receptor blockade with haloperidol, buspirone further enhanced DA neuronal impulse flow. Buspirone did not cause catalepsy and did not inhibit apomorphine-induced turning in rats with unilateral 6-hydroxydopamine lesions of the substantia nigra, which indicated that the drug has minimal action at the classical postsynaptic DA receptor. These data suggest that (a) buspirone enhances DA neuronal activity, in part, by weakly inhibiting presynaptic DA receptors, and (b) buspirone has minimal effects on postsynaptic DA receptors.

UR - http://www.scopus.com/inward/record.url?scp=0020536004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020536004&partnerID=8YFLogxK

M3 - Article

C2 - 6131948

AN - SCOPUS:0020536004

VL - 3

SP - 733

EP - 738

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 4

ER -